U.S. court invalidates J&J cancer drug patent, hitting UK's BTG

NEW YORK (Reuters) - A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .